Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. 2013

Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
Department of Neurology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan. Electronic address: yshimizu@nij.twmu.ac.jp.

Osteopontin (OPN) up-regulates pro-inflammatory cytokines from both T helper type 1 and T helper type 17 cell pathways. We measured plasma OPN levels in Japanese multiple sclerosis (MS) and neuromyelitis optica (NMO) patients to investigate its value as a potential biomarker of disease activity. In NMO patients, plasma OPN levels were significantly higher than those in healthy individuals, being equivalent to those in MS patients. In both NMO and MS patients, OPN levels were significantly higher during relapse compared with remission. There was also a significant positive correlation between Expanded Disability Status Scale of Kurzke scores and plasma OPN levels in both NMO and MS patients, and plasma OPN levels were significantly higher in patients with secondary progressive MS compared with those with relapsing-remitting MS. Diagnostic sensitivity and specificity of plasma OPN for MS and NMO during the relapse phase were 100% and 50%, respectively (cut-off point: 31.3ng/ml). Thus, elevated plasma OPN levels could be a potential biomarker for not only MS but also NMO. These are the first results to suggest that plasma OPN in NMO patients may be a useful marker, playing an important role in inflammation, disease activity, and disease progression, as well as MS.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D009471 Neuromyelitis Optica A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4. Devic Disease,Devic's Neuromyelitis Optica,Devic Neuromyelitis Optica,Devic Syndrome,Devic's Disease,Devic's Syndrome,NMO Spectrum Disorder,Neuromyelitis Optica (NMO) Spectrum Disorder,Neuromyelitis Optica (NMO) Spectrum Disorders,Neuromyelitis Optica Spectrum Disorder,Neuromyelitis Optica Spectrum Disorders,Devic Neuromyelitis Opticas,Devics Disease,Devics Neuromyelitis Optica,Devics Syndrome,Disease, Devic,Disease, Devic's,NMO Spectrum Disorders,Neuromyelitis Optica, Devic,Neuromyelitis Optica, Devic's,Neuromyelitis Opticas, Devic,Syndrome, Devic,Syndrome, Devic's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D053495 Osteopontin A negatively-charged extracellular matrix protein that plays a role in the regulation of BONE metabolism and a variety of other biological functions. Cell signaling by osteopontin may occur through a cell adhesion sequence that recognizes INTEGRIN ALPHA-V BETA-3. Bone Sialoprotein 1,Bone Sialoprotein I,Secreted Phosphoprotein 1,Sialoprotein 1,Uropontin,Sialoprotein 1, Bone,Sialoprotein I, Bone

Related Publications

Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
June 2013, Multiple sclerosis (Houndmills, Basingstoke, England),
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
February 2012, Journal of neuroimmunology,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
January 1969, Neurologia, psihiatria, neurochirurgia,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
July 2012, Journal of neurochemistry,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
April 2004, Journal of neuroimmunology,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
January 2005, Journal of neuroimmunology,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
February 2015, Gene,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
November 2011, Rinsho shinkeigaku = Clinical neurology,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
December 2016, Noro psikiyatri arsivi,
Yuko Shimizu, and Kohei Ota, and Ryotaro Ikeguchi, and Sachiko Kubo, and Chiaki Kabasawa, and Shinichiro Uchiyama
September 1970, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!